News | February 01, 2023
Sun Pharma Q3 FY23 Gross Sales up 13.1%; Net profit up 5.2%
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
It will help upgrade the infrastructure and technologies of the country's biopharmaceuticals and in-vitro diagnostic industry
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
India's G20 Presidency will focus on three main priorities: Health Emergencies Prevention, Preparedness and Response (One Health & AMR); Access and Availability to Affordable Medical Countermeasures (Vaccines, Therapeutics, and Diagnostics); and Digital Health
The centre has initiated next generation sequencing (NGS) as a tool for undertaking studies on genomic epidemiology of pathogens
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
Subscribe To Our Newsletter & Stay Updated
